Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Hideyuki Iwayama, Taichiro Muto, Hitomi Amano, Akihisa Okumura, Tomohito Hayakawa, Yoshiro Kitagawa
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-4 (2021)
Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-4 (2021)
Background Glucocorticoids rarely cause anaphylaxis. Common methods for the determination of allergens include in vivo skin prick test (SPT) and intradermal skin test (IDST) and the in vitro basophil activation test (BAT). However, to our knowledge,
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-8 (2021)
Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-8 (2021)
Backgrounds Chronic urticaria is a common disorder of the skin, characterised by recurrent skin wheals and angioedema. Recent reports have shown that altered diversity and composition of the gut microbiota may lead to imbalances in immune regulation,
Autor:
Koichi Jingo, Jun Ito, Toshihiko Nishioki, Haruhi Takagi, Tomohito Takeshige, Kazuhisa Takahashi, Norihiro Harada, Tomoko Yamada, Tetsuhiko Asao, Masahiro Torasawa
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-6 (2020)
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-6 (2020)
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the
Autor:
Jean Bousquet, Glenis Scadding, Marek L. Kowalski, Iñaki Izquierdo, Antonio Valero, Joaquim Mullol
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-9 (2020)
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-9 (2020)
Background The clinical efficacy of rupatadine in terms of responders has not been previously explored in perennial allergic rhinitis (PAR). Methods This pooled analysis included data from 6 randomised, double-blind, placebo-controlled trials conduct
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-4 (2019)
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-4 (2019)
Background There are numerous biologics for treating patients with severe asthma. A cost-effective method for selecting the most appropriate biologic therapy for a patient is thus important. Bronchoscopy-guided bronchial epithelium sampling may provi
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-2 (2019)
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-2 (2019)
Amyopathic dermatomyositis has been associated with the exposure to several drugs: the article by Jeimy et al. described the onset of this uncommon disease in a patient treated with omalizumab. Paradoxically, this patient complained of an intense pru
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-5 (2019)
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-5 (2019)
Background Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-4 (2019)
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-4 (2019)
We report a male with longstanding warts who presented with severe West Nile virus encephalitis (WNVE) and recovered after interferon alfa-2b and intravenous immunoglobulin. He was later found to have GATA2 deficiency and underwent successful hematop
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Background Angioedema due to acquired deficiency of C1-inhibitor (C1-INH-AAE) is a rare disease sharing some clinical and laboratory similarities with hereditary angioedema, but with late onset and no positive family history. The underlining cause ma
Autor:
Charlotte A. Slade, Pasquale L. Fedele, Michael Sze Yuan Low, Leisa Rebecca Watson, Samar Ojaimi, Justine E. Marum, Sebastian Lunke, Vanessa L. Bryant, Sara Barnes, Prudence Smith, Matthew F. Hunter, Zornitza Stark
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Background Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune